Pharmaceutical protein production by yeast: Towards production of human blood proteins by microbial fermentation

Current Opinion in Biotechnology

Volumn 23, Issue 6, 2012, Pages 965-971

  Martínez, José L ^a   Liu, Lifang ^a   Petranovic, Dina ^a   Nielsen, Jens ^a,b  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^b Chalmers University of Technology   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PROTEIN; CLINICAL USE; CURRENT SITUATION; GENOMICS; HIGH-THROUGHPUT ANALYSIS; HUMAN BLOOD PROTEINS; LARGE SCALE PRODUCTIONS; MICROBIAL CELLS; MICROBIAL FERMENTATION; MODEL PLATFORM; PHARMACEUTICAL PROTEIN; SYSTEMS BIOLOGY; THERAPEUTIC PROTEIN; YEAST SACCHAROMYCES CEREVISIAE;

ESCHERICHIA COLI; YEAST;

RECOMBINANT PROTEINS;

ALPHA2B INTERFERON; ANGIOSTATIN; APOLIPOPROTEIN A1; BLOOD CLOTTING FACTOR 7A; FIBRINOGEN; GONADOTROPIN; HEPATITIS B VACCINE; HIRUDIN; HUMAN INSULIN; HUMAN SERUM ALBUMIN; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HEMOGLOBIN; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFERRIN; WART VIRUS VACCINE;

BIOTECHNOLOGY; FERMENTATION; FUNGAL STRAIN; GENETIC ENGINEERING; HUMAN; METABOLIC ENGINEERING; MICROBIAL FERMENTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN SECRETION; REVIEW; SACCHAROMYCES CEREVISIAE; SITE DIRECTED MUTAGENESIS; SYSTEMS BIOLOGY;

BLOOD PROTEINS; FERMENTATION; HEMOGLOBINS; HUMANS; PROTEIN BIOSYNTHESIS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SYSTEMS BIOLOGY;

ESCHERICHIA COLI; SACCHAROMYCES CEREVISIAE;

EID: 84869870745     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2012.03.011     Document Type: Review

References (67)

1. Ferrer-Miralles N., Domingo-Espin J., Corchero J.L., Vazquez E., Villaverde A. Microbial factories forrecombinant pharmaceuticals. Microb Cell Fact 2009, 8:17.
2. Redwan E.-R. Cumulative updating of approved biopharmaceuticals. Hum Antibodies 2007, 16:22.
3. Goodman M. Market watch: sales of biologics to show robust growth through to 2013. Nat Rev Drug Discov 2009, 8:837.
4. Aggarwal S. What's fueling the biotech engine-2010 to 2011. Nat Biotechnol 2011, 29:1083-1089.
5. Terpe K. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 2006, 72:211-222.
6. Panda A.K. Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli. Adv Biochem Eng Biotechnol 2003, 85:43-93.
7. Porro D., Gasser B., Fossati T., Maurer M., Branduardi P., Sauer M., Mattanovich D. Production of recombinant proteins and metabolites in yeasts: when are these systems better than bacterial production systems?. Appl Microbiol Biotechnol 2011, 89:939-948.
8. Tripathi N.K., Jana S.K., Rao A.M. PVL: high yield production of heterologous proteins with Escherichia coli. Defence Sci J 2009, 59:137-146.
9. Walsh G., Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006, 24:1241-1252.
10. De Pourcq K., De Schutter K., Callewaert N. Engineering of glycosylation in yeast and other fungi: current state and perspectives. Appl Microbiol Biotechnol 2010, 87:1617-1631.
11. Nolan R.P., Lee K. Dynamic model for CHO cell engineering. J Biotechnol 2012, 158:24-33.
12. Morrow K.J. Improving protein production processes. Gen Eng News 2007, 27:50-54.
13. Cox M.M. Recombinant protein vaccines produced in insect cells. Vaccine 2012, 30:1759-1766.
14. Celik E., Calik P. Production of recombinant proteins by yeast cells. Biotechnol Adv 2012, 30:1108-1118.
15. Demain A.L., Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 2009, 27:297-306.
16. Gerngross T.U. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 2004, 22:1409-1414.
17. Hou J., Tyo K., Liu Z., Petranovic D., Nielsen J. Engineering of vesicle trafficking improves heterologous protein secretion in Saccharomyces cerevisiae. Metab Eng 2012.
18. Amano K., Chiba Y., Kasahara Y., Kato Y., Kaneko M.K., Kuno A., Ito H., Kobayashi K., Hirabayashi J., Jigami Y., et al. Engineering of mucin-type human glycoproteins in yeast cells. Proc Natl Acad Sci U S A 2008, 105:3232-3237.
19. Chigira Y., Oka T., Okajima T., Jigami Y. Engineering of a mammalian O-glycosylation pathway in the yeast Saccharomyces cerevisiae: production of O-fucosylated epidermal growth factor domains. Glycobiology 2008, 18:303-314.
20. Graf A., Dragosits M., Gasser B., Mattanovich D. Yeast systems biotechnology for the production of heterologous proteins. FEMS Yeast Res 2009, 9:335-348.
21. Kim I.K., Roldao A., Siewers V., Nielsen J. A systems-level approach for metabolic engineering of yeast cell factories. FEMS Yeast Res 2012, 12:228-248.
22. Krivoruchko A., Siewers V., Nielsen J. Opportunities for yeast metabolic engineering: lessons from synthetic biology. Biotechnol J 2011, 6:262-276.
23. Holz C., Prinz B., Bolotina N., Sievert V., Bussow K., Simon B., Stahl U., Lang C. Establishing the yeast Saccharomyces cerevisiae as a system for expression of human proteins on a proteome-scale. J Struct Funct Genomics 2003, 4:97-108.
24. Schröder M. Endoplasmic reticulum stress responses. Cell Mol Life Sci 2008, 65:862-894.
25. Tyo K., Liu Z., Petranovic D., Nielsen J. Imbalance of heterologous protein folding and disulfide bond formation rates yields runaway oxidative stress. BMC Biol 2012, 10:16.
26. Liu Z., Tyo K., Martínez J.L., Petranovic D., Nielsen J. Different expression systems for production of recombinant proteins in Saccharomyces cerevisiae. Biotechnol Bioeng 2012, 109:1259-1268.
27. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol 2010, 28:917-924.
28. Kobayashi K. Summary of recombinant human serum albumin development. Biologicals 2006, 34:55-59.
29. Chuang V., Otagiri M. Recombinant human serum albumin. Drugs Today 2007, 43:547.
30. Tojo N., Miyagi I., Miura M., Ohi H. Recombinant human fibrinogen expressed in the yeast Pichia pastoris was assembled and biologically active. Protein Expr Purif 2008, 59:289-296.
31. Agarwal S., Singh R., Sanyal I., Amla D. Expression of modified gene encoding functional human α-1-antitrypsin protein in transgenic tomato plants. Transgenic Res 2008, 17:881-896.
32. Brandsma M.E., Jevnikar A.M., Ma S. Recombinant human transferrin: beyond iron binding and transport. Biotechnol Adv 2011, 29:230-238.
33. Nagai K., Thøgersen H.C. Synthesis and sequence-specific proteolysis of hybrid proteins produced in Escherichia coli. Methods Enzymol 1987, 153:461-481.
34. Shen T.J., Ho N.T., Simplaceanu V., Zou M., Green B.N., Tam M.F., Ho C. Production of unmodified human adult hemoglobin in Escherichia coli. Proc Natl Acad Sci 1993, 90:8108-8112.
35. Hoffman S., Looker D., Roehrich J., Cozart P., Durfee S., Tedesco J., Stetler G. Expression of fully functional tetrameric human hemoglobin in Escherichia coli. Proc Natl Acad Sci U S A 1990, 87:8521-8525.
36. Hernan R., Hui H., Andracki M., Noble R., Sligar S., Walder J., Walder R. Human hemoglobin expression in Escherichia coli: importance of optimal codon usage. Biochemistry 1992, 31:8619-8628.
37. Looker D., Abbott-Brown D., Cozart P., Durfee S., Hoffman S., Mathews A.J., Miller-Roehrkh J., Shoemaker S., Trimble S., Fermi G. A human recombinant haemoglobin designed for use as a blood substitute. Nature 1992, 356:258-260.
38. Feng L., Gell D.A., Zhou S., Gu L., Kong Y., Li J., Hu M., Yan N., Lee C., Rich A.M. Molecular mechanism of AHSP-mediated stabilization of α-hemoglobin. Cell 2004, 119:629-640.
39. Feng L., Zhou S., Gu L., Gell D.A., Mackay J.P., Weiss M.J., Gow A.J., Shi Y. Structure of oxidized α-haemoglobin bound to AHSP reveals a protective mechanism for haem. Nature 2005, 435:697-701.
40. Vasseur-Godbillon C., Hamdane D., Marden M., Baudin-Creuza V. High-yield expression in Escherichia coli of soluble human {alpha}-hemoglobin complexed with its molecular chaperone. Protein Eng Des Sel 2006, 19:91-97.
41. Manjula B.N., Kumar R., Sun D.P., Ho N.T., Ho C., Rao J.M., Malavalli A., Acharya A.S. Correct assembly of human normal adult hemoglobin when expressed in transgenic swine: chemical, conformational and functional equivalence with the human-derived protein. Protein Eng 1998, 11:583-588.
42. Kim M.D., Yoo Y.J., Rhee S.K., Seo J.H. Enhanced transformation efficiency of an anticoagulant hirudin gene into Saccharomyces cerevisiae by a double delta-sequence. J Microbiol Biotechnol 2001, 11:61-64.
43. Ginzburg Y.Z., Rybicki A.C., Suzuka S.M., Hall C.B., Breuer W., Cabantchik Z.I., Bouhassira E.E., Fabry M.E., Nagel R.L. Exogenous iron increases hemoglobin in β-thalassemic mice. Exp Hematol 2009, 37:172-183.
44. Dieryck W., Pagnier J., Poyart C., Marden M.C., Gruber V., Bournat P., Baudino S., Mérot B. Human haemoglobin from transgenic tobacco. Nature 1997, 386:29.
45. Adachi K., Konitzer P., Kim J., Welch N., Surrey S. Effects of beta 6 aromatic amino acids on polymerization and solubility of recombinant hemoglobins made in yeast. J Biol Chem 1993, 268:21650-21656.
46. Martin de Llano J., Schneewind O., Stetler G., Manning J. Recombinant human sickle hemoglobin expressed in yeast. Proc Natl Acad Sci U S A 1993, 90:918.
47. Olson JS, Weiss MJ, Enhancing recombinant hemoglobin production by co-expression with alpha hemoglobin stabilizing protein. Google Patents; 2010.
48. Mollan T.L., Yu X., Weiss M.J., Olson J.S. The role of alpha-hemoglobin stabilizing protein in redox chemistry, denaturation, and hemoglobin assembly. Antioxid Redox signal 2010, 12:219-231.
49. Fibach E., Kollia P., Schechter A., Noguchi C., Rodgers G. Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin. Blood 1995, 85:2967-2974.
50. Weickert M.J., Curry S.R. Turnover of recombinant human hemoglobin in Escherichia coli occurs rapidly for insoluble and slowly for soluble globin. Arch Biochem Biophys 1997, 348:337-346.
51. Franken A.C.W., Lokman B.C., Ram A.F.J., Punt P.J., van den Hondel C.A., de Weert S. Heme biosynthesis and its regulation: towards understanding and improvement of heme biosynthesis in filamentous fungi. Appl Microbiol Biotechnol 2011, 91:447-460.
52. Hoffman M., Góra M., Rytka J. Identification of rate-limiting steps in yeast heme biosynthesis. Biochem Biophys Res Commun 2003, 310:1247-1253.
53. Kim M.D., Lee T.H., Lim H.K., Seo J.H. Production of antithrombotic hirudin in GAL1-disrupted Saccharomyces cerevisiae. Appl Microbiol Biotechnol 2004, 65:259-262.
54. Avgerinos G.C., Turner B.G., Gorelick K.J., Papendieck A., Weydemann U., Gellissen G. Production and clinical development of a Hansenula polymorpha-derived PEGylated hirudin. Semin Thromb Hemost 2001, 27:357-372.
55. Degelmann A., Muller F., Sieber H., Jenzelewski V., Suckow M., Strasser A.W., Gellissen G. Strain and process development for the production of human cytokines in Hansenula polymorpha. FEMS Yeast Res 2002, 2:349-361.
56. Graumann K., Premstaller A. Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 2006, 1:164-186.
57. Xie J., Zhang L., Ye Q., Zhou Q., Xin L., Du P., Gan R. Angiostatin production in cultivation of recombinant Pichia pastoris fed with mixed carbon sources. Biotechnol Lett 2003, 25:173-177.
58. Ning D., Junjian X., Xunzhang W., Wenyin C., Qing Z., Kuanyuan S., Guirong R., Xiangrong R., Qingxin L., Zhouyao Y. Expression, purification, and characterization of humanized anti-HBs Fab fragment. J Biochem 2003, 134:813-817.
59. Fleer R., Chen X.J., Amellal N., Yeh P., Fournier A., Guinet F., Gault N., Faucher D., Folliard F., Fukuhara H., et al. High-level secretion of correctly processed recombinant human interleukin-1 beta in Kluyveromyces lactis. Gene 1991, 107:285-295.
60. Schmidt F.R. Recombinant expression systems in the pharmaceutical industry. Appl Microbiol Biotechnol 2004, 65:363-372.
61. Kobayashi K., Kuwae S., Ohya T., Ohda T., Ohyama M., Ohi H., Tomomitsu K., Ohmura T. High-level expression of recombinant human serum albumin from the methylotrophic yeast Pichia pastoris with minimal protease production and activation. J Biosci Bioeng 2000, 89:55-61.
62. Punt P.J., van Biezen N., Conesa A., Albers A., Mangnus J., van den Hondel C. Filamentous fungi as cell factories for heterologous protein production. Trends Biotechnol 2002, 20:200-206.
63. Schmidt H.H., Genschel J., Haas R., Buttner C., Manns M.P. Expression and purification of recombinant human apolipoprotein A-I in Chinese hamster ovary cells. Protein Expr Purif 1997, 10:226-236.
64. Gurramkonda C., Polez S., Skoko N., Adnan A., Gabel T., Chugh D., Swaminathan S., Khanna N., Tisminetzky S., Rinas U. Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin. Microb Cell Fact 2010, 9:31.
65. Grillberger L., Kreil T.R., Nasr S., Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 2009, 4:186-201.
66. Monie A., Hung C.F., Roden R., Wu T.C. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008, 2:97-105.
67. Pyle L.E., Barton P., Fujiwara Y., Mitchell A., Fidge N. Secretion of biologically active human proapolipoprotein A-I in a baculovirus-insect cell system: protection from degradation by protease inhibitors. J Lipid Res 1995, 36:2355-2361.